Wearables may improve heart failure care and outcomes
Wearable devices developed in recent years can potentially improve care and outcomes of patients with heart failure (HF).
“Biosensing wearables, including vests, socks, watches, rings, glasses, patches, tattoos on pill boxes or food, and ingestible pills, can be used to collect data from HF patients for analysis. The goals are to promote wellness, prevent hospitalizations, and facilitate titration of guideline-directed medical therapy [GDMT] through optimizing care coordination and improving the value of care provided,” said Dr Adam DeVore of Duke University Medical School and Duke Clinical Research Institute in Durham, North Carolina, US.
For example, a US FDA-approved remote dielectric sensing system (ReDS) in the form of a wearable vest enables assessment of intrathoracic fluid in patients with HF. A recent single-centre study demonstrated significant lung decongestion with ReDS-guided management of patients hospitalized with acute HF, but did not show a reduction in HF readmissions. [Heart Lung 2020, doi: 10.1016/j.hrtlng.2020.07.003]
Randomized trials are evaluating the role of wearable devices as part of a digital health platform in improving GDMT use among patients with HF with reduced ejection fraction. For example, the HF-eVOLUTION trial is evaluating a wristwatch for remote monitoring of vital signs, while the AIM-POWER trial is assessing a cloud-based clinical decision support platform comprising an artificial intelligence software and wearable biosensors. [NCT04292275; NCT04191330]
“Wearable devices can be connected through a mobile phone across home, work, recreational and automobile settings, which are then connected to the hospital,” DeVore suggested. “They have great potential in improving HF care, which may result in improved patient outcomes.” [JACC Heart Fail 2019;7:922-932]